Takeda and Pfizer expand Japanese arthritis alliance
This article was originally published in Scrip
Pfizer and Takeda have agreed to extend their alliance for the co-promotion of Enbrel (etanercept) in Japan and have also joined forces for the promotion in this market of Pfizer's investigational rheumatoid arthritis (RA) therapy, tofacitinib.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.